Volume 6, Issue 4 (10-2002)                   IBJ 2002, 6(4): 123-128 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Alimohammadian M H, Darabi H, Kariminia A, Rivier D, Bovay P, Mauel J, et al . Adjuvant Effect of Leishmania major Promastigotes on the Immune Response of Mice to Ovalbumin. IBJ 2002; 6 (4) :123-128
URL: http://ibj.pasteur.ac.ir/article-1-557-en.html
Abstract:  
The immune responses of mice immunized with ovalbumin (OVA) together with killed L. major (KLM) promastigotes as adjuvant were studied. Three doses (5 × 107, 1 × 108 and 2 × 108) of KLM combined with OVA (100 mg) were injected into the groups of C57BL/6 mice. BCG and complete Freund’s adjuvant (CFA) were used as control adjuvants. Lymphocyte proliferation and antibody titers were determined, and IFN-g and IL-4 were measured in the supernatants of lymph node cell cultures. Results showed that immunization using OVA mixed with KLM enhanced the in vitro proliferative response of T-cells to the antigen and resulted in the production of increased levels of IFN-g (2800-3700 pg/ml) relative to the mice injected with OVA alone (1750 pg/ml). In the mice receiving OVA + 5 × 107 KLM, the production of IL-4 remained lower (18, 20 pg/ml) than OVA alone (105, 109 pg/ml) and almost was similar to that of observed in mice inoculated with OVA + BCG, leading to high IFN-g/IL-4 ratios. Using higher doses of KLM (1 × 108), the IL-4 responses were of the same magnitude as or higher than the responses of mice inoculated with OVA + CFA. Antibody titers to OVA were also strongly boosted at the highest KLM dose. These findings indicate that KLM may function as an adjuvant, and its dose plays a role in the eventual outcome of the response. Inoculation of the mice with a low dose of KLM (5 × 107) tends to promote a Th1-type response .
Type of Study: Full Length/Original Article |

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Iranian Biomedical Journal

Designed & Developed by : Yektaweb